摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-2-cyclohexylpropan-1-ol | 5442-00-2

中文名称
——
中文别名
——
英文名称
(S)-2-cyclohexylpropan-1-ol
英文别名
(S)-2-cyclohexyl-propan-1-ol;(2S)-2-cyclohexylpropan-1-ol
(S)-2-cyclohexylpropan-1-ol化学式
CAS
5442-00-2;86990-95-6;120201-26-5
化学式
C9H18O
mdl
——
分子量
142.241
InChiKey
IRIVQXLOJHCXIE-MRVPVSSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    219.85°C (rough estimate)
  • 密度:
    0.9000
  • LogP:
    2.655 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2906199090

SDS

SDS:739bb687e36a7b70900f3d931f463f1d
查看

反应信息

  • 作为反应物:
    描述:
    (S)-2-cyclohexylpropan-1-ol2,4,6-三甲基吡啶N-氯代丁二酰亚胺silver nitrate三乙胺 、 sodium iodide 作用下, 以 四氢呋喃 为溶剂, 生成 (R)-2-Cyclohexyl-4-trimethylsilanyl-octan-4-ol
    参考文献:
    名称:
    Non-chelation controlled 1,3-asymmetric induction in β-chiral acylsilanes
    摘要:
    The diastereoselectivity of nucleophilic adition to beta-chiral acylsilanes is examined, and our method is applied to the stereoselective synthesis of calcitriol lactone, a major metabolite of vitamine D-3.
    DOI:
    10.1016/s0040-4039(00)75805-9
  • 作为产物:
    描述:
    (S)-2-Cyclohexylpropanoic acid 在 lithium aluminium tetrahydride 、 乙醚 作用下, 生成 (S)-2-cyclohexylpropan-1-ol
    参考文献:
    名称:
    Studies in Stereochemistry. XX. Steric Control of Asymmetric Induction in the Preparation of the 3-Cyclohexyl-2-butanol System1
    摘要:
    DOI:
    10.1021/ja01119a067
点击查看最新优质反应信息

文献信息

  • Determination of the Absolute Configuration of β-Chiral Primary Alcohols Using the Competing Enantioselective Conversion Method
    作者:Alexander S. Burns、Alexander J. Wagner、Jennifer L. Fulton、Kyle Young、Armen Zakarian、Scott. D. Rychnovsky
    DOI:10.1021/acs.orglett.7b01189
    日期:2017.6.2
    A method for determining the absolute configuration of β-chiral primary alcohols has been developed. Enantioenriched alcohols were acylated in the presence of either enantiomer of the enantioselective acylation catalyst HBTM, and the faster reaction was determined by measuring product conversion using 1H NMR spectroscopic analysis. An empirical mnemonic was developed that correlates the absolute configuration
    已经开发出确定β-手性伯醇的绝对构型的方法。在对映选择性酰化催化剂HBTM的任何一种对映异构体的存在下,将富含对映体的醇酰化,并通过使用1 H NMR光谱分析测量产物转化率来确定更快的反应。开发了经验助记符,其将醇的绝对构型与更快反应的催化剂相关联。该方法成功的底物包括在立体异构中心带有“指导基团”的伯醇。指导基团包括芳烃,杂芳烃,烯酮和卤化物。
  • [EN] GAMMA AMINO ACID BUILDING BLOCKS<br/>[FR] ÉLÉMENTS CONSTITUTIFS DE GAMMA-AMINOACIDES
    申请人:WISCONSIN ALUMNI RES FOUND
    公开号:WO2011047190A1
    公开(公告)日:2011-04-21
    The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a pro line derivative to provide cyclically constrained α-substituted-γ-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to cyclically constrained protected γ- amino acid residues, which are essential for systematic conformational studies of γ-peptide foldamers. New methods are also provided to prepare other γ-amino acids and peptides. These new building blocks can be used to prepare foldamers, such as α/γ-peptide foldamers, that adopt specific helical conformations in solution and in the solid state.
    该发明提供了化合物和方法,例如,用于催化贝氏碱衍生物对环状约束硝基乙烯化合物进行醛的有机催化Michael加成,从而提供环状约束的α-取代-γ-硝基醛。当使用手性吡咯烷催化剂时,反应可以实现对映选择性,从而以几乎光学纯形式(例如,96%至>99% e.e.)获得Michael加合物。Michael加合物可以在羰基相邻处携带单取代基或双取代基。Michael加合物可以高效转化为环状约束的保护γ-氨基酸残基,这对于γ-肽折叠体系的系统构象研究至关重要。还提供了制备其他γ-氨基酸和肽的新方法。这些新的构建模块可用于制备折叠体,例如α/γ-肽折叠体,在溶液中和固态中采用特定螺旋构象。
  • Smac mimetic dimers and trimers useful as anti-cancer agents
    申请人:Joyant Pharmaceuticals, Inc.
    公开号:US20140127155A1
    公开(公告)日:2014-05-08
    The invention provides small molecule mimics of the Smac peptide that are dimer-like or trimer-like compounds having two or three amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
    这项发明提供了Smac肽的小分子类似物,它们是二聚体或三聚体化合物,具有由连接剂连接的两个或三个含酰胺的结构域。这些化合物有助于促进细胞凋亡。该发明包括包含这些化合物的药物组合物和使用它们治疗癌症和自身免疫性疾病等病症的方法。
  • Benzolactam compounds as protein kinase inhibitors
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:US10457669B2
    公开(公告)日:2019-10-29
    The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
    本发明提供了一种式 (0) 的化合物: 或其药学上可接受的盐、N-氧化物或同系物;其中 n 是 1 或 2 X 是 CH 或 N Y 选自 CH 和 C-F Z 选自 C-Rz 和 N; R1 选自 -(Alk1)t-Cyc1;其中 t 为 0 或 1; 任选取代的 C1-6 无环烃基团 R2 选自氢、卤素和任选被一个或多个原子取代的 C1-3 烃基; R3 是氢或基团 L1-R7; R4 选自氢、甲氧基和任选被取代的 C1-3 烷基;以及 R4a 选自氢和 C1-3 烷基; 其中 Rz、Alk1、Cyc1、L1 和 R7 在本文中定义; 只要该化合物不是 6-苄基-3-2-[(2-甲基嘧啶-4-基)基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮和 3-2-[(2-甲基嘧啶-4-基)基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮及其盐和它们的同系物。 这些化合物是 ERK1/2 激酶的抑制剂,可用于治疗 ERK1/2 介导的疾病。因此,这些化合物可用于治疗,特别是治疗癌症。
  • Zirconium-catalyzed enantioselective methylalumination of monosubstituted alkenes
    作者:Denis Y. Kondakov、Ei-ichi Negishi
    DOI:10.1021/ja00148a031
    日期:1995.11
查看更多